Sai Life Sciences surges as Q2 PAT rises 17% YoY
Revenue from operations increased 22.7% YoY to Rs 659 crore in Q2 FY27 from Rs 537 crore in Q2 FY26. On a sequential basis, revenue rose 19.0% from Rs 554 crore in Q1 FY27.
EBITDA rose 19.9% YoY to Rs 187 crore from Rs 156 crore. Sequentially, EBITDA increased 26.4% from Rs 148 crore.
EBITDA margin stood at 28% against 29% in the year-ago quarter and 27% in Q1 FY27.
Profit before tax rose 17.0% YoY to Rs 131 crore from Rs 112 crore. It increased 33.7% QoQ from Rs 98 crore in Q1 FY27.
Total expenses increased 20.5% YoY to Rs 531.27 crore in Q2 FY27. Cost of materials, chemicals and reagents consumed rose 17.1% YoY to Rs 170.07 crore from Rs 145.18 crore. Employee benefits expense increased 21.7% YoY to Rs 198.06 crore from Rs 162.79 crore. Finance costs rose 17.0% to Rs 10.94 crore, while depreciation and amortisation increased 21.1% to Rs 48.13 crore.
The company's CDMO business contributed 64% of revenue, while CRO accounted for the remaining 36%. Capacity utilisation stood at 67% in Q2 FY27.
The company incurred capital expenditure of Rs 621 crore during H1 FY27, including Rs 358 crore in Q2. It remains on track to achieve its overall capex projection of Rs 1,100-1,300 crore.
Managing Director and CEO Krishna Kanumuri said Q2 FY27 was a strong quarter, supported by continued business momentum and progress across key strategic priorities. He highlighted growing traction with global pharmaceutical companies, increased adoption of the integrated outsourcing model and the expansion of capacity and capabilities.
Chief Financial Officer Siva Chittor said the performance was broad-based, with both CRO and CDMO businesses delivering healthy growth. He added that the company expects a stronger second half, supported by the progression of its development and commercial pipeline and the ramp-up of new capacity.
Sai Life Sciences is a Hyderabad-based Contract Research, Development and Manufacturing Organization (CRDMO) that provides drug discovery, development and manufacturing services to pharmaceutical and biotechnology companies. Its operations span process development, clinical and commercial manufacturing, and advanced technology platforms, with a global customer base.
Powered by Capital Market - Live News